Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties

Journal of Medicinal Chemistry

Volumn 47, Issue 26, 2004, Pages 6490-6498

  Tumiatti, Vincenzo ^a   Andrisano, Vincenza ^a   Banzi, Rita ^a   Bartolini, Manuela ^a   Minarini, Anna ^a   Rosini, Michela ^a   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; CAPROCTAMINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; LIGAND; MUSCARINIC M2 RECEPTOR ANTAGONIST; PHYSOSTIGMINE; PIPERIDINE DERIVATIVE; POLYAMINE DERIVATIVE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CHOLINESTERASE INHIBITION; DRUG ACTIVITY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVE SITE; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; AMYLOID BETA-PROTEIN; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; HUMANS; PIPERIDINES; POLYAMINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10644228563     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0494366     Document Type: Article

References (30)

1. Bachurin, S. O. Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease. Med. Res. Rev. 2003, 23, 48-88.
2. Roberson, M. R.; Harrell, L. E. Cholinergic activity and amyloid precursor protein metabolism. Brain Res. Rev. 1997, 25, 50-69.
3. Tariot, P. N.; Federoff, H. J. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis. Assoc. Disord. 2003, 17 (Suppl. 4), S105-113.
4. Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003, 2, 539-547.
5. Kasa, P.; Rakonczay, Z.; Gulya, K. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 1997, 52, 511-535.
6. Gualtieri, F.; Dei, S.; Manetti, D.; Romanelli, M. N.; Scapecchi, S.; Teodori, E. The medicinal chemistry of Alzheimer's and Alzheimer-like diseases with emphasis on the cholinergic hypothesis. Farmaco 1995, 50, 489-503.
7. Brufani, M.; Filocamo, L.; Lappa, S.; Maggi, A. New acetylcholinesterase inhibitors. Drugs Future 1997, 22, 397-410.
8. Small, D. H.; Michaelson, S.; Sberna, G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem. Int. 1996, 28, 453-483.
9. Soreq, H.; Seidman, S. Acetylcholinesterase: new roles for an old actor. Nat. Rev. Neurosci. 2001, 2, 294-302.
10. von Bernhardi, R.; Ramirez, G.; De Ferrari, G. V.; Inestrosa, N. C. Acetylcholinesterase induces the expression of the β-amyloid precursor protein in glia and activates glial cells in culture. Neurobiol. Dis. 2003, 14, 447-457.
11. Rees, T.; Hammond, P. I.; Soreq, H.; Younkin, S.; Brimijoin, S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol. Aging 2003, 24, 777-787.
12. Alvarez, A.; Alarcon, R.; Opazo, C.; Campos, E. O.; Munoz, F. J.; Calderon, F. H.; Dajas, F.; Gentry, M. K.; Doctor, B. P.; De Mello, F. G.; Inestrosa, N. C. Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci. Res. 1998, 18, 3213-3223.
13. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 2001, 40, 10447-10457.
14. Chatonnet, A.; Lockridge, O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 1989, 260, 625-634.
15. Moran, M. A.; Mufson, E. J.; Gomez-Ramos, P. Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol. 1993, 85, 362-369.
16. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16, 881-891.
17. Massoulie, J.; Sussman, J.; Bon, S.; Silman, I. Structure and functions of acetylcholinesterase and butyrylcholinesterase. Prog. Brain Res. 1993, 98, 139-146.
18. Melchiorre, C.; Antonello, A.; Banzi, R.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V. Polymethylene tetraamine backbone as template for the development of biologically active polyamines. Med. Res. Rev. 2003, 23, 200-233.
19. Bolognesi, M. L.; Minarini, A.; Budriesi, R.; Cacciaguerra, S.; Chiarini, A.; Spampinato, S.; Tumiatti, V.; Melchiorre, C. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists. J. Med. Chem. 1998, 41, 4150-4160.
20. Melchiorre, C.; Andrisano, V.; Bolognesi, M. L.; Budriesi, R.; Cavalli, A.; Cavrini, V.; Rosini, M.; Tumiatti, V.; Recanatini, M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J. Med. Chem. 1998, 41, 4186-4189.
21. Tumiatti, V.; Rosini, M.; Bartolini, M.; Cavalli, A.; Marucci, G.; Andrisano, V.; Angeli, P.; Banzi, R.; Minarini, A.; Recanatini, M.; Melchiorre, C. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. J. Med. Chem. 2003, 46, 954-966.
22. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A new rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
23. Minarini, A.; Bolognesi, M. L.; Budriesi, R.; Canossa, M.; Chiarini, A.; Spampinato, S.; Melchiorre, C. Design, synthesis, and biological activity of methoctramine-related tetraamines bearing an 11-acetyl-5,11-dihydro-6H-pyrido[2, 3-b][1,4]benzodiazepin-6-one moiety: structural requirements for optimum occupancy of muscarinic receptor subtypes as revealed by symmetrical and unsymmetrical polyamines. J. Med. Chem. 1994, 37, 3363-3372.
24. Van Rossum, J. M. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. Ther. 1963, 143, 299-330.
25. Snape, M. F.; Misra, A.; Murray, T. K.; De Souza, R. J.; Williams, J. L.; Cross, A. J.; Green, A. R. A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology 1999, 38, 181-193.
26. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl(methyl) amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem. 2003, 46, 2279-2282.
27. Inestrosa, N. C.; Alvarez, A.; Calderon, F. Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid β-peptide into Alzheimer's filaments. Mol. Psychiatry 1996, 1, 359-361.
28. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 2003, 65, 407-416.
29. Giacobini, E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging 2001, 18, 891-898.
30. Motulsky, H. J. Analyzing Data with GraphPad Prism; Graph-Pad Software Inc.: San Diego, CA, 1999.